University Hospital Ghent-led Nationwide Belgium Study Reveals Rhematic Drugs Like Tocilizumab Fail to Treat COVID-19 Patients

University Hospital Ghent-led Nationwide Belgium Study Reveals Rhematic Drugs Like Tocilizumab Fail to Treat COVID-19 Patients

Further evidence suggests rheumatic drugs fail to treat effectively COVID-19 patients, such as the results from a recent Ghent University study in Belgium known as the COV-AID study. Led by Principal Investigator Bart Lambrecht, the Belgian findings from this study covering 342 patients in 16 hospitals calls into question the use of drugs such as tocilizumab (Actemra) and for that matter other similar agents such as siltuximab (Sylvant) and anakinra (Kineret) for treating COVID-19. The Belgian-based investigators report that these drugs had no effect on recovery, length of hospital stay, or survival despite some experiments in places such as the Netherlands that had “encouraging” data points. TrialSite has chronicled tocilizumab and other IL-6 inhibitor studies demonstrating that the majority of the clinical trials involving this class of drug fail to result in efficacious outcomes. A few studies have showed some positive impact (Notably REMAP-CAP) mixed interpretation results, and that hasn’t stopped record sales as $600 million of the total $3 billion revenue for tocilizumab (Actemra) derive from COVID-19 patient treatments. In America, the National Institutes of Health (NIH) CO...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee